274 related articles for article (PubMed ID: 31030372)
41. A physiological view and structures of mean residence times.
Durišová M
Gen Physiol Biophys; 2014; 33(1):75-80. PubMed ID: 24334531
[TBL] [Abstract][Full Text] [Related]
42. In vitro-in vivo correlation in P-glycoprotein mediated transport in intestinal absorption.
del Amo EM; Heikkinen AT; Mönkkönen J
Eur J Pharm Sci; 2009 Feb; 36(2-3):200-11. PubMed ID: 19063964
[TBL] [Abstract][Full Text] [Related]
43. Comparison of pharmacokinetics of newly discovered aromatase inhibitors by a cassette microdosing approach in healthy Japanese subjects.
Kusuhara H; Takashima T; Fujii H; Takashima T; Tanaka M; Ishii A; Tazawa S; Takahashi K; Takahashi K; Tokai H; Yano T; Kataoka M; Inano A; Yoshida S; Hosoya T; Sugiyama Y; Yamashita S; Hojo T; Watanabe Y
Drug Metab Pharmacokinet; 2017 Dec; 32(6):293-300. PubMed ID: 29137842
[TBL] [Abstract][Full Text] [Related]
44. Influence of dose range on degree of nonlinearity detected in dose-proportionality studies for drugs with saturable elimination: single-dose and steady-state studies.
Shepard TA; Lordi N; Sparrow PE
Pharm Res; 1993 Feb; 10(2):289-93. PubMed ID: 8456079
[TBL] [Abstract][Full Text] [Related]
45. Sensitivity-based analytical approaches to support human absolute bioavailability studies.
Xu XS; Jiang H; Christopher LJ; Shen JX; Zeng J; Arnold ME
Bioanalysis; 2014 Feb; 6(4):497-504. PubMed ID: 24568352
[TBL] [Abstract][Full Text] [Related]
46. Ethical, legal, and social implications (ELSI) of microdose clinical trials.
Kurihara C
Adv Drug Deliv Rev; 2011 Jun; 63(7):503-10. PubMed ID: 21251940
[TBL] [Abstract][Full Text] [Related]
47. A review of drug solubility in human intestinal fluids: implications for the prediction of oral absorption.
Augustijns P; Wuyts B; Hens B; Annaert P; Butler J; Brouwers J
Eur J Pharm Sci; 2014 Jun; 57():322-32. PubMed ID: 23994640
[TBL] [Abstract][Full Text] [Related]
48. Intestinal drug transporter expression and the impact of grapefruit juice in humans.
Glaeser H; Bailey DG; Dresser GK; Gregor JC; Schwarz UI; McGrath JS; Jolicoeur E; Lee W; Leake BF; Tirona RG; Kim RB
Clin Pharmacol Ther; 2007 Mar; 81(3):362-70. PubMed ID: 17215845
[TBL] [Abstract][Full Text] [Related]
49. A timely reassessment of early prediction in the bioavailability of orally administered drugs.
Larsen T; Link A
Angew Chem Int Ed Engl; 2005 Jul; 44(29):4432-4. PubMed ID: 15984039
[No Abstract] [Full Text] [Related]
50. Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter.
Mangas-Sanjuan V; Navarro-Fontestad C; García-Arieta A; Trocóniz IF; Bermejo M
Eur J Pharm Sci; 2018 May; 117():193-203. PubMed ID: 29452210
[TBL] [Abstract][Full Text] [Related]
51. Influence of posture on pharmacokinetics.
Queckenberg C; Fuhr U
Eur J Clin Pharmacol; 2009 Feb; 65(2):109-19. PubMed ID: 18936930
[TBL] [Abstract][Full Text] [Related]
52. Microdose clinical trial: quantitative determination of nicardipine and prediction of metabolites in human plasma.
Yamane N; Takami T; Tozuka Z; Sugiyama Y; Yamazaki A; Kumagai Y
Drug Metab Pharmacokinet; 2009; 24(4):389-403. PubMed ID: 19745565
[TBL] [Abstract][Full Text] [Related]
53. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.
Ring BJ; Chien JY; Adkison KK; Jones HM; Rowland M; Jones RD; Yates JW; Ku MS; Gibson CR; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
J Pharm Sci; 2011 Oct; 100(10):4090-110. PubMed ID: 21541938
[TBL] [Abstract][Full Text] [Related]
54. Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans.
Hohmann N; Kocheise F; Carls A; Burhenne J; Haefeli WE; Mikus G
Br J Clin Pharmacol; 2015 Feb; 79(2):278-85. PubMed ID: 25588320
[TBL] [Abstract][Full Text] [Related]
55. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein.
Tachibana T; Kato M; Takano J; Sugiyama Y
Curr Drug Metab; 2010 Nov; 11(9):762-77. PubMed ID: 21189139
[TBL] [Abstract][Full Text] [Related]
56. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.
Tubic M; Wagner D; Spahn-Langguth H; Bolger MB; Langguth P
Pharm Res; 2006 Aug; 23(8):1712-20. PubMed ID: 16832615
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of Model-Based Prediction of Pharmacokinetics in the Renal Impairment Population.
Yee KL; Li M; Cabalu T; Sahasrabudhe V; Lin J; Zhao P; Jadhav P
J Clin Pharmacol; 2018 Mar; 58(3):364-376. PubMed ID: 29077203
[TBL] [Abstract][Full Text] [Related]
58. The influence of hepatic transport on the distribution volumes and mean residence time of drug in the body and the accuracy of estimating these parameters by the traditional pharmacokinetic calculations.
Berezhkovskiy LM
J Pharm Sci; 2011 Nov; 100(11):5031-47. PubMed ID: 21766310
[TBL] [Abstract][Full Text] [Related]
59. An Assessment of the Oral Bioavailability of Three Ca-Channel Blockers Using a Cassette-Microdose Study: A New Strategy for Streamlining Oral Drug Development.
Yamashita S; Kataoka M; Suzaki Y; Imai H; Morimoto T; Ohashi K; Inano A; Togashi K; Mutaguchi K; Sugiyama Y
J Pharm Sci; 2015 Sep; 104(9):3154-61. PubMed ID: 26037531
[TBL] [Abstract][Full Text] [Related]
60. Application of a statistical method to the absorption of a new model drug from micellar and lipid formulations--evaluation of qualitative excipient effects.
Kuentz M; Wyttenbach N; Kuhlmann O
Pharm Dev Technol; 2007; 12(3):275-83. PubMed ID: 17613891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
